Loading
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Latest quote
$40.10
+$0.05 · +0.12%
After-hours
$40.10
$0.00 · 0.00%
Oct 9, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Day range
Current $40.10
52-week range
Current $40.10
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
66
Bullish
Risk
33
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Day range
Current $40.10
52-week range
Current $40.10
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 276.26M USD | 237.22M USD | 197.52M USD | 164.37M USD | 156.18M USD |
| Cost of goods sold | 70.66M USD | 65.12M USD | 61.94M USD | 54.58M USD | 50.16M USD |
| Gross profit | 205.6M USD | 172.11M USD | 135.58M USD | 109.79M USD | 106.03M USD |
| Research and development | 27.56M USD | 24.8M USD | 21.04M USD | 19.94M USD | 16.29M USD |
| Selling, general, and administrative | 166.99M USD | 142.79M USD | 121M USD | 106.9M USD | 97.59M USD |
| Operating expenses | 194.56M USD | 167.59M USD | 142.04M USD | 126.85M USD | 113.88M USD |
| Interest income | 7.01M USD | 6.41M USD | 4.63M USD | 1.34M USD | 224K USD |
| Interest expense | 1.56M USD | 614K USD | 600K USD | 366K USD | 4K USD |
| Depreciation and amortization | 11.36M USD | 5.5M USD | 4.63M USD | 3.98M USD | 2.97M USD |
| Operating income | 11.04M USD | 4.52M USD | −6.46M USD | −17.06M USD | −7.85M USD |
| Net income | 16.52M USD | 10.36M USD | −3.18M USD | −16.71M USD | −7.47M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$61.33
52.94% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 16, 2013 | 1:20 | — | — |
Stock split | Feb 18, 2010 | 1:8 | — | — |
Effective Oct 16, 2013
1:20
Effective Feb 18, 2010
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI64.73M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM54.09M0.07%77.7B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI45.85M0.45%10.11B USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF23.71M0.02%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO19.1M0.14%14.04B USD0.24%$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM18.82M0.12%15.8B USD0.03%$53.45+0.17%
iShares Biotechnology ETFIBB15.7M0.15%10.41B USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS15.08M0.04%33.8B USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
